IASLC Foundation

 

 

 Donate Now

 

We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

IASLC 17th World Conference
on Lung Cancer (WCLC)

 

 

IASLC 18th World Conference on
Lung Cancer

October 15-18, 2017 | Yokohama, Japan

#WCLC2017

2017 ALCF-IASLC Joint Fellowship Award

 

Application Submission Deadline: March 1, 2017

IASLC Small Cell Lung Cancer Workshop

March 16 - 17, 2017 | New York City, New York

Issue Four of IASLC Lung Cancer News - Now Available!

Featured Science and Communiqués

Histologic Classification Impacts the Efficacy of SBRT Treatment in Early-Stage Lung Cancer Patients

Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.

Evolution of the Individualized Treatment Landscape for Advanced NSCLC: A Scientific Summary

This document was created based on the satellite symposium entitled "Evolution of the Individualized Treatment Landscape for Advanced NSCLC." This symposium was held during the IASLC Asia Pacific Lung Cancer Conference (APLCC 2016).

Individualized Treatment of Advanced NSCLC: A Scientific Summary

These documents were produced through satellite symposium entitled "Individualizing the Treatment of Advanced NSCLC," held at the IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016).

HC-Based NGS Impacts Treatment Decisions in Lung Cancer Patients with Adenocarcinoma

DENVER – The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.